Lv51
1030 积分 2024-11-29 加入
Reframing the “Rescue Window”: From Physiological Upper Bounds to Actionable Thresholds
1天前
已完结
Ethics of Backfilling in Early-Phase Oncology Trials
8天前
已关闭
Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2–Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial
8天前
已完结
Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody–drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study
8天前
已完结
Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody–drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study
8天前
已完结
Aneuploidy as a driver of human cancer
10天前
已完结
Tumor aneuploidy as a prognostic and predictive biomarker in immune checkpoint blockade
10天前
已完结
Targeting chromosomal instability and aneuploidy in cancer
10天前
已完结
Adjuvant Durvalumab in Completely Resected Early-Stage Non–Small Cell Lung Cancer
20天前
已完结
The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology
20天前
已完结
皖公网安备34019202002308
